3,9-difluoro-12,13-dihydro-12-[4-fluoro-4-deoxy-β-D-glucopyranosyl]-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione | 406913-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,9-difluoro-12,13-dihydro-12-[4-fluoro-4-deoxy-β-D-glucopyranosyl]-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
• 英文别名: BMS-250749；12-[4-deoxy-4-fluoro-β-D-glucopyranosyl]-3,9-difluoro-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione；5H-Indolo(2,3-a)pyrrolo(3,4-C)carbazole-5,7(6H)-dione, 12-(4-deoxy-4-fluoro-beta-D-glucopyranosyl)-3,9-difluoro-12,13-dihydro-；7,19-difluoro-3-[(2R,3R,4R,5S,6R)-5-fluoro-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
• CAS: 406913-72-2
• 化学式: C₂₆H₁₈F₃N₃O₆
• 分子量: 525.441
• InChiKey: MUXIBMYSVWHKJF-KLQAUAMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  38
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  137
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  生成 3,9-difluoro-12,13-dihydro-12-[4-fluoro-4-deoxy-β-D-glucopyranosyl]-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
  参考文献：
  名称：

  J. Med. Chem. 2005, 48, 2258-2261

  摘要：

  DOI：

文献信息

• Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
  申请人：——

  公开号：US20030083271A1

  公开（公告）日：2003-05-01

  The present invention relates to fluoro sugar and other sugar derivatives of indolopyrrolocarbazoles, their salts and hydrates, which exhibit selective topoisomerase I (topo I) activity, are useful in inhibiting the proliferation of tumor cells and exhibit an antitumor effect, as well as processes for their preparation.

  本发明涉及氟糖和其他印度洋红咔唑衍生物的糖衍生物，其盐和水合物具有选择性拓扑异构酶I（topo I）活性，对抑制肿瘤细胞增殖和表现出抗肿瘤效果有用，以及它们的制备过程。
• Discovery of a Fluoroindolo[2,3-<i>a</i>]carbazole Clinical Candidate with Broad Spectrum Antitumor Activity in Preclinical Tumor Models Superior to the Marketed Oncology Drug, CPT-11
  作者：Mark G. Saulnier、Balu N. Balasubramanian、Byron H. Long、David B. Frennesson、Edward Ruediger、Kurt Zimmermann、Jeffrey T. Eummer、Denis R. St. Laurent、Karen M. Stoffan、B. Narasimhulu Naidu、Mikael Mahler、Francis Beaulieu、Carol Bachand、Frank Y. Lee、Craig R. Fairchild、Linda K. Stadnick、William C. Rose、Carola Solomon、Henry Wong、Alain Martel、John J. Wright、Robert Kramer、David R. Langley、Dolatrai M. Vyas

  DOI：10.1021/jm049090z

  日期：2005.4.1

  A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity. The lead clinical candidate from this series, BMS-250749, displays broad spectrum antitumor activity superior to CPT-11 against some preclinical xenograft models, including curative antitumor activity against Lewis lung carcinoma.
• J. Med. Chem. 2005, 48, 2258-2261
  作者：

  DOI：——

  日期：——